Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer

被引:21
作者
Cruz-Rico, Graciela [1 ]
Aviles-Salas, Alejandro [3 ]
Segura-Gonzalez, Manuel [2 ]
Maria Espinosa-Garcia, Ana [4 ]
Alejandra Ramirez-Tirado, Laura [1 ]
Morales-Oyarvide, Vicente [2 ]
Rojas-Marin, Carlos [3 ]
Cardona, Andres-Felipe [5 ]
Arrieta, Oscar [1 ,2 ]
机构
[1] Hosp Gen Mexico City, Expt Oncol Lab, Mexico City, DF, Mexico
[2] Hosp Gen Mexico City, Clin Thorac Oncol, Mexico City, DF, Mexico
[3] Hosp Gen Mexico City, Inst Nacl Cancerol INCan, Dept Pathol, Mexico City, DF, Mexico
[4] Hosp Gen Mexico City, Gen Med Lab, Mexico City, DF, Mexico
[5] Clin Cty, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2017年 / 40卷 / 06期
关键词
non-small cell lung carcinoma; anaplastic lymphoma kinase; routine diagnostic tests; immunohistochemistry; real-time polymerase chain reaction; ANAPLASTIC LYMPHOMA; FUSION GENE; ALK REARRANGEMENT; KINASE; ADENOCARCINOMA; CRIZOTINIB; INHIBITOR; FEATURES; IDENTIFICATION; CHEMOTHERAPY;
D O I
10.1097/COC.0000000000000213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess anaplastic lymphoma kinase (ALK) rearrangement detection with immunohistochemistry (IHC) and real-time polymerase chain reaction (RT-qPCR) in comparison with fluorescence in situ hybridization (FISH). Methods: Tumor tissue samples from 230 patients with advanced non-small cell lung cancer (NSCLC) were analyzed by FISH to detect ALK rearrangements. Additional IHC tests using 5A4 clone and RT-qPCR (variants 1 to 5) were performed in 63 and 48 patients, respectively. Results: Thirteen percent of FISH tests were not evaluable. From the remaining tests (n = 200), 18 (9.0%) were ALK positive (ALK(+)). ALK(+) patients were significantly younger at the time of diagnosis (below 55 y, 14.3% vs. 5.5%, P = 0.035), were light smokers (tobacco index < 10, 12.6% vs. 4.1%, P = 0.049), and presented adenocarcinoma with a mucinous component (30.8 vs. 8.0%, P = 0.007). When comparing FISH with IHC using a cutoff of 1 + or 2 +, and only 2 + staining intensity, the sensitivity, specificity, negative predictive value, and positive predictive value were as follows: 83.3%, 100.0%, 93.75%, and 100.0%; and 55.6%, 100.0%, 84.9%, and 100.0%, respectively. For RT-qPCR, these results were 55.6, 100, 90.7, and 100.0%, respectively. Conclusions: Our results suggest that RT-qPCR is an inadequate initial test for detecting ALK-positive lung cancer. IHC is highly useful as an initial screening test for ALK rearrangement detection in NSCLC. These results contribute to the medical literature on the establishment of IHC as a standard diagnostic test for ALK rearrangements in NSCLC.
引用
收藏
页码:631 / 638
页数:8
相关论文
共 50 条
  • [41] Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer
    Luo, Lian-Xiang
    Li, Ying
    Niu, Yu-Zhen
    Wang, Yu-Wei
    Wang, Qian-Qian
    Fan, Xing-Xing
    Xu, Jia-Hui
    Liu, Liang
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    MEDCHEMCOMM, 2017, 8 (10) : 1914 - 1918
  • [42] EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
    Gower, Arjan
    Hsu, Wei-Hsun
    Hsu, Shuo-Tse
    Wang, Yisong
    Giaccone, Giuseppe
    MOLECULAR ONCOLOGY, 2016, 10 (04) : 601 - 609
  • [43] EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries
    Elshatlawy, Mariam
    Sampson, Josephina
    Clarke, Katy
    Bayliss, Richard
    MOLECULAR ONCOLOGY, 2023, 17 (06) : 950 - 963
  • [44] Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer
    Zou, Zihua
    Wu, Lige
    Hao, Xuezhi
    Li, Yan
    Liang, Li
    Gu, Yangchun
    Ying, Jianming
    Li, Junling
    Xing, Puyuan
    THORACIC CANCER, 2025, 16 (02)
  • [45] Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4-ALK Fusion Gene
    Takahashi, Tsuyoshi
    Sonobe, Makoto
    Kobayashi, Masashi
    Yoshizawa, Akihiko
    Menju, Toshi
    Nakayama, Ei
    Mino, Nobuya
    Iwakiri, Shotaro
    Sato, Kiyoshi
    Miyahara, Ryo
    Okubo, Kenichi
    Manabe, Toshiaki
    Date, Hiroshi
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (03) : 889 - 897
  • [46] Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
    Zhang, Ling
    Li, Yunxia
    Zhang, Shaohong
    Gao, Chen
    Nie, Keke
    Ji, Youxin
    CANCER BIOLOGY & MEDICINE, 2018, 15 (02) : 178 - 181
  • [47] EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer
    Ren, Weihong
    Zhang, Bo
    Ma, Jie
    Li, Wencai
    Lan, Jianyun
    Men, Hui
    Zhang, Qinxian
    ONCOLOGY LETTERS, 2015, 10 (06) : 3385 - 3392
  • [48] Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer
    Tufman, Amanda
    Kahnert, Kathrin
    Duell, Thomas
    Kauffmann-Guerrero, Diego
    Milger, Katrin
    Schneider, Christian
    Stump, Julia
    Syunyaeva, Zulfiya
    Huber, Rudolf Maria
    Reu, Simone
    ONCOTARGETS AND THERAPY, 2017, 10 : 5179 - 5186
  • [49] Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis
    Wang, Ying
    Wang, Shumin
    Xu, Shiguang
    Qu, Jiaqi
    Liu, Bo
    PLOS ONE, 2014, 9 (10):
  • [50] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Graham, Donna M.
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey
    Tsao, Ming S.
    Cutz, Jc
    Leighl, Natasha
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1317 - S1318